Drug Development: The Review Record Behind Asset Decisions
Drug-development teams rarely lose time because one source is missing.
They lose time because the source is somewhere else. Clinical trials in one place. Publications in another. Regulatory records, patents, company filings, investor decks, data-room records, reviewer notes, and clinical-strategy rationale scattered across separate workflows.
AuraOne Drug Development is built around that problem: one asset record, one source trail, and one reviewed record.
What is proven today
The current product implementation supports the core workflow shape:
- Asset scouting and external program review
- Scientific diligence with source-cited claims, assumptions, risks, and gaps
- Clinical strategy with trial sources, endpoint precedents, and indication hypotheses
- Human review before assisted-live or unreviewed sources can drive applied worker output
- Diligence, indication, and decision records with citations, provider modes, hashes, source lists, and audit metadata
- Provider health and provenance labels so users can distinguish fixtures, assisted-live research, live public APIs, enterprise connectors, and licensed-vendor abstractions
That matters because a portfolio decision is only useful if the team can inspect the sources and reviewer notes behind it later.
The source layer
The platform now has provider adapters for the source classes a drug-development team needs most often:
- ClinicalTrials.gov for clinical trial records
- PubMed, Europe PMC, Crossref, and OpenAlex for literature
- FDA Drugs@FDA and DailyMed for regulatory and label records
- PatentsView for patent metadata
- ChEMBL and PubChem for chemistry sources
- Open Targets for target-validation sources
- SEC EDGAR for public company filings
The web research provider is separate. It can help discover sources across the web, but it is always assisted-live and review-gated. It does not become authoritative source material until a reviewer accepts it.
The abstraction layer
Some source classes should not be marketed as production integrations until a customer has credentials, source allowlists, or a licensed vendor contract. AuraOne tracks those honestly as source abstractions.
That includes EU and global registries, EMA, EPO OPS, WIPO/Lens, BindingDB, RCSB PDB, GWAS Catalog, GEO/Expression Atlas, DepMap/cBioPortal, conference abstracts, investor-deck ingestion, Snowflake/S3, Benchling/Dotmatics, Veeva/Medidata, and licensed competitive-intelligence vendors.
Those entries are useful now because they give settings, health checks, source records, and workers a consistent provenance contract. They are not represented as credentialed customer integrations until the customer environment actually has access.
The decision workflow
The workflow is intentionally simple.
First, the team starts with an asset, target, company, indication, or diligence question. AuraOne searches configured public providers and assisted web sources, then brings candidate source material into the asset record.
Second, reviewers accept, reject, edit, and attach sources. Review state stays visible. Source URLs, provider record IDs, retrieval timestamps, source domains, and content hashes travel with the source material.
Third, workers produce diligence, clinical, risk, or decision outputs. The outputs are schema-validated and source-grounded. Unsupported claims and unreviewed sources are blocked or flagged before the output can be applied.
Fourth, the team exports a reviewed record. The file carries accepted sources, claims, assumptions, risks, gaps, worker notes, source lists, provider modes, and a verification hash.
That record is what the next reviewer, portfolio lead, or governance process can inspect.
Fifth, reviewed outcomes become evaluation or training signal where the workflow explicitly supports it. The accepted sources and reviewer judgments improve the next diligence pass without turning a review record into an unsupported model-ownership claim.
What we do not claim yet
This is not a claim of full market parity with any production drug-development intelligence vendor.
AuraOne should not yet claim production customer deployment proof, licensed competitive-intelligence data access, or live integrations with every enterprise system.
The accurate claim is narrower and stronger:
AuraOne has shipped an implementation-level Drug Development with live public biomedical and company-intelligence providers, assisted web research, enterprise connector abstractions, review-gated specialist workers, benchmark scaffolding, and source provenance.
That is the product surface now available to build from.
What teams keep
The durable asset is the record:
- Accepted and rejected sources
- Provider provenance and content hashes
- Reviewer notes and review state
- Clinical context and endpoint precedents
- Claims, assumptions, risks, and gaps
- Review records and audit files
- Strategy memory and rejected hypotheses
- Handoff files and handoff terms the team can inspect later
This is a managed App Data app for your field. The work does not disappear into a slide deck, a shared folder, or a black-box answer. It stays attached to the asset.
---
Ready to run asset diligence on one record?
-> Drug Development -> App Data -> Talk to us
